Current Psychopharmacology最新文献

{"title":"Psilocybin in the Management of Substance Use Disorders: A Summary of\u0000Current Evidence","authors":"Hussein El Bourji, Aziz Farhat, Zahi Hamdan, Ritvij M Satodiya, Rashmi Shukla, S. El Hayek","doi":"10.2174/0122115560288779240628043307","DOIUrl":"https://doi.org/10.2174/0122115560288779240628043307","url":null,"abstract":"\u0000\u0000Following clinical trials on psilocybin for the treatment of pain, anxiety,\u0000and depression in patients with cancer, scientific interest emerged in its use for substance use disorders.\u0000\u0000\u0000\u0000In this review of the literature, we summarize available trials looking at the use of psilocybin in addiction\u0000\u0000\u0000\u0000One double-blind, randomized clinical trial looked at the effect of psilocybin on heavy\u0000drinking in adults diagnosed with alcohol dependence. Several trials are currently ongoing to assess\u0000psilocybin’s efficacy in the management of different SUDs. Otherwise, the current evidence is insufficient to derive any conclusions on the possible efficacy of psilocybin in substance use disorders.\u0000\u0000\u0000\u0000More well-powered, blinded, randomized controlled trials are needed to investigate\u0000the possible therapeutic effects of psilocybin in addiction while identifying the appropriate conditions that promote its safe use.\u0000","PeriodicalId":10751,"journal":{"name":"Current Psychopharmacology","volume":"22 s43","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141683743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Have We Placed the Cart Before the Horse by Using Alpha-2 Agonists to\u0000Treat Rejection Sensitivity Dysphoria in ADHD?","authors":"William W. Dodson, E. Modestino","doi":"10.2174/0122115560297397240404071044","DOIUrl":"https://doi.org/10.2174/0122115560297397240404071044","url":null,"abstract":"<jats:sec>\u0000<jats:title />\u0000<jats:p />\u0000</jats:sec>","PeriodicalId":10751,"journal":{"name":"Current Psychopharmacology","volume":"72 9","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140736265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Neuroanatomy, Etiopathogenesis, and Novel Therapeutic Targets in\u0000Depressive Disorders","authors":"Indu Arora, Kunal Khurana, Manish Kumar","doi":"10.2174/0122115560281804240102054639","DOIUrl":"https://doi.org/10.2174/0122115560281804240102054639","url":null,"abstract":"\u0000\u0000Depression has a high prevalence and associated comorbidities. It is still unknown what\u0000the molecular basis of depression is, regardless of many theories that have been put up to explain it.\u0000Many researchers investigate that present-day therapies for depression are ineffective due to their\u0000low efficacy, delayed onset of action (typically two weeks), and adverse effects. Novel medications\u0000that operate more quickly and effectively are thus needed. Several novel molecules (e.g., ketamine,\u0000buprenorphine) have been proven to produce quick and dependable antidepressant benefits in depressive\u0000patients who are resistant to treatment; yet, questions about their effectiveness, possible\u0000abuse, and adverse effects persist. The molecular basis and pharmacological interventions for depression\u0000were included in this study. Even if pharmaceutical treatments for depression have mostly\u0000failed to alleviate the condition, identifying and addressing possible risk factors in an effort to reduce\u0000the prevalence of this psychiatric disease is beneficial for public health. We emphasized the\u0000neuroanatomy and etiopathogenesis of depression, along with a discussion of the putative pharmacological\u0000mechanisms, novel targets, research hurdles, and prospective therapeutic futures.\u0000","PeriodicalId":10751,"journal":{"name":"Current Psychopharmacology","volume":"13 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139613782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Comprehensive Review on the Neuropharmacological Effects of Antidepressants in Various Prospects","authors":"Sandesh Varshney, Md. Aftab Alam, Awaneet Kaur, Shaweta Sharma","doi":"10.2174/2211556011666230707122341","DOIUrl":"https://doi.org/10.2174/2211556011666230707122341","url":null,"abstract":"Abstract: Depression is one of the most challenging diseases for society to treat. It is a highly prevalent and disabling illness in the general population. Affective disorders are characterised by depressed mood, diminished interest and pleasure, feelings of guilt or poor self-worth, sleep or food difficulties, decreased energy, and impaired attention. This manuscript will look at depression from a behavioural analytic perspective. The pathogenesis of major depressive disorder is poorly understood. Several lines of experimental and clinical evidence, however, show that the therapeutic effect of most antidepressant drugs is related to an increase in 5-HT-mediated neurotransmission. Alternative techniques, however, are employed to obtain this net effect. A better understanding of the neurological mechanism underpinning antidepressant drugs' delayed onset of action has resulted in the development of ways to accelerate antidepressant responses, which are discussed further below. Many antidepressant medications on the market today are beneficial, but they come with many downsides, including unpleasant side effects, potential interactions, and a low response rate. Natural drugs, on the other hand, are extremely effective, have a low risk, and a limited amount of side effects, which are covered briefly in this paper. Alternative modalities of administration have received a lot of attention in recent decades as a complement to approved prescription pharmaceuticals, especially for people who cannot tolerate oral or parenteral methods. The most promising non-invasive systemic delivery techniques are transdermal and transbronchial administration, and these are the focus of this research.","PeriodicalId":10751,"journal":{"name":"Current Psychopharmacology","volume":"25 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135840238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardio-Pshyco-Pharmacology: A Review","authors":"Dulaanga Rathnayake, A. A. N. Nishad, Sepalika Mendis","doi":"10.2174/2211556011666230330094933","DOIUrl":"https://doi.org/10.2174/2211556011666230330094933","url":null,"abstract":"\u0000\u0000Cardiovascular and psychiatric diseases are leading causes of morbidity and mortality worldwide. Cardiovascular adverse events related to psychopharmacology have been well-known for decades. They increase the cardio-metabolic risk factor profile. Obesity, hypertension, diabetes mellitus (DM), and dyslipidemia are highly prevalent among patients with psychiatric disorders. Clozapine and olanzapine are known to cause severe hypertriglyceridemia. \u0000Drugs, such as aripiprazole, clozapine, olanzapine, and ziprasidone, increase the prevalence of hypertension, and atypical antipsychotics are known to cause orthostatic hypotension. The most common and popular arrhythmia, Torsades de pointes, due to QT prolongation, is a known side effect of typical and atypical antipsychotics. Sudden deaths, myocarditis, and cardiomyopathies are other common cardiac side effects of psycopharmacotherapy. \u0000Thus, pharmacovigilance is more important for both psychiatrists and cardiologists/physicians when evaluating patients with these common presentations and not to miss the etiological agents.\u0000","PeriodicalId":10751,"journal":{"name":"Current Psychopharmacology","volume":"26 2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81574898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of SSRI Use on the Clinical Outcome and Prognosis of COVID-19 Patients: A Single-Center Prospective Study","authors":"F. Boroujerdi, M. Safa, S. Ziai, A. Moniri, Farzaneh Haji Zadeh, A. Soheili, Siamak Afaghi, F. Rahimi, Bamdad Mirab Zadeh Ardekani","doi":"10.2174/2211556011666221027124605","DOIUrl":"https://doi.org/10.2174/2211556011666221027124605","url":null,"abstract":"\u0000\u0000Recent studies have found a link between the usage of selective serotonin reuptake inhibitors (SSRIs) and a lower mortality rate in COVID-19 cases.\u0000\u0000\u0000\u0000The goal of current research was evaluating the effectiveness of SSRI drugs on improvement of COVID-19 patients.\u0000\u0000\u0000\u0000This prospective case-control study, compared SSRI-treated patients with matched control patients not treated with SSRIs at Masih Daneshvari Hospital on a population of 350 patients diagnosed with COVID-19 from March 15th 2021 to March 16th 2022.\u0000\u0000\u0000\u0000ICU admission rates were significantly more in the control group than in the case group (44.8% vs. 25.9%; p-value=0.0002; Odds Ratio (OR)= 2.32). Intubation was reported for more cases in the control group than the case group (26.7% vs. 11.4%; p-value=0.0002; OR=2.84). Mortality rate was found to be significantly more in the control group than the case group (23.0% vs. 10.8%; p-value=0.0002; OR=2.46). Furthermore, the subgroup analyses on Fluvoxamine and Sertraline showed that Hospitalization period, ICU admission rates, and intubation were all reported to be significantly smaller in each case subgroups as against the control group.\u0000\u0000\u0000\u0000Our assessments underlined the potential efficacy of SSRIs in improving COVID-19 patients’ prognosis, since the use of SSRIs were shown to be associated with shorter hospital stay and ICU stay, lower ICU admission rates and intubation rates, and ultimately decreased mortality rates.\u0000","PeriodicalId":10751,"journal":{"name":"Current Psychopharmacology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75337587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Exploratory Study Using the Anti-Anxiety Medication Buspirone for Driving Anxiety in Autism Spectrum Disorder","authors":"R. Fried, Maura Di Salvo, Bruce Mehler, Thomas McWilliams, Haley Driscoll, Chloe Hutt Vater, J. Biederman","doi":"10.2174/2211556011666220817090452","DOIUrl":"https://doi.org/10.2174/2211556011666220817090452","url":null,"abstract":"\u0000\u0000The literature documents that intellectually capable autism spectrum disorder\u0000(ASD) is frequently associated with driving avoidance. Because ASD is associated with high levels of\u0000comorbid anxiety and our previous work suggested heightened anxiety during driving simulation, we\u0000evaluated whether driving behavior assessed through a driving simulator would improve with antianxiety medication.\u0000\u0000\u0000\u0000This was an open label, proof of concept, testing the usefulness and tolerability of the nonsedating, short acting anti-anxiety medication buspirone using a randomly assigned crossover design.\u0000\u0000\u0000\u0000The sample consisted of 24 adult drivers (5 female) with DSM-V ASD (mean age 28.4\u0000years) who completed two simulated driving sessions, one while taking the anti-anxiety medication\u0000buspirone and one without it.\u0000\u0000\u0000\u0000Treatment with buspirone was associated with significantly improved driving performance as\u0000measured by less variability in lane positioning, a proxy for safer driving, lower self-report anxiety\u0000scores on items involving physical sensations, and better self-report scores on the ability to concentrate while driving.\u0000\u0000\u0000\u0000These preliminary, proof of concept findings suggest that mitigating anxiety may improve driving performance in individuals with intellectually capable ASD, supporting the need to conduct larger controlled studies assessing this important issue.\u0000","PeriodicalId":10751,"journal":{"name":"Current Psychopharmacology","volume":"18 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78303326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive Review on Ethnopharmacological and Phytochemical Aspects of Nutraceuticals in Psychiatric Disorders","authors":"Samir G Patel, Niraj Vyas, Alkesh Patel, Umang Shah, M. Raval, Mehul Patel, Archita J Patel","doi":"10.2174/2211556011666220510141329","DOIUrl":"https://doi.org/10.2174/2211556011666220510141329","url":null,"abstract":"\u0000\u0000Ageing comes with degeneration in many biological activities like impairment of cognition, intelligence, attention, and memory. The decline in all those mental capabilities would be due to the abnormal changes in neuronal architecture with increasing age, chronic oxidative stress and inflammatory state of the tissue, nutritional deficiency. Nootropics or smart drugs enhance memory, attention, creativity, and cognitive performance by affecting the synthesis and receptor binding of neurotransmitters in the brain, especially dopamine, serotonin, gamma-aminobutyric acid, glutamate, and acetylcholine. Nootropics have shown their positive effects in parkinson's, autism, alzheimer's, huntington's disorders, where impaired memory is the primary concern. Synthetic class of nootropics has limitations and reported exacerbation of other brain disorders (off label effects) or therapeutic failure in some instances. Nutraceuticals are dietary derived vitamins, minerals, herbal products, proteins, marine products, and probiotics. The health benefits derived from Nutraceuticals are increasing brain blood flow, reducing inflammation in nervous tissues, detoxifying toxins from the brain, balancing neurotransmitter turnover rate, correcting neuronal and receptor damages and facilitating synaptic transmission, good antioxidant properties and power of improving neuroplasticity of the brain that combat neurodegeneration. The demands for effective nootropics will remain high as the number of cases are increased tremendously.\u0000","PeriodicalId":10751,"journal":{"name":"Current Psychopharmacology","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75557249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cocaine administration protects gut mucosa barrier and reduces plasma level of TNF-α.","authors":"Xiaoyu Fu, Chuanxiu Bian, Anna Kruyer, Zejun Zhou, Zhenwu Luo, Azizul Haque, Amanda Wagner, Ren Lang, Sylvia Fitting, Catrina Robinson, Aimee McRae-Clark, Davide Amato, Wei Jiang","doi":"10.2174/2211556011666220818091709","DOIUrl":"10.2174/2211556011666220818091709","url":null,"abstract":"<p><strong>Background: </strong>Cocaine affects not only the central nervous system, but also systemic immunity. The role of cocaine in gut mucosal integrity is not fully understood.</p><p><strong>Methods: </strong>Here we evaluated the effect of cocaine use on gut endothelial permeability and system inflammation in rats that self-administered cocaine or saline and in humans using immunohistochemistry, qPCR, ELISA, and Transepithelial/transendothelial electrical resistance (TEER).</p><p><strong>Results: </strong>Cocaine administration maintained intact and undisturbed intestinal mucosal structures, increased tight junction claudin 1 and 2 mRNA expression, and decreased plasma TNF-α levels, compared to the control group, at the end of study in rats. Further, cocaine treatment decreased gut endothelial permeability in a dose-dependent manner in human epithelial Caco-2 cells <i>in vitro</i>. Consistently, chronic cocaine users exhibited decreased plasma levels of TNF-α compared with non-drug users <i>in vivo</i>. However, plasma IL-6 levels were similar between cocaine use and control groups both in humans and rats <i>in vivo</i>.</p><p><strong>Conclusions: </strong>Our results from both human and rat studies <i>in vivo</i> and <i>in vitro</i> suggest that cocaine use may exert a protective effect on the integrity of gut mucosa and suppresses plasma TNF-α levels. This study may provide information on some beneficial effects of cocaine use on gut endothelial cells integrity and systemic inflammation.</p>","PeriodicalId":10751,"journal":{"name":"Current Psychopharmacology","volume":"11 2","pages":"1-8"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9974179/pdf/nihms-1832033.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10866122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dopaminylation in Psychostimulant Use Disorder Protects Against Psychostimulant Seeking Behavior by Normalizing Nucleus Accumbens (NAc) Dopamine Expression.","authors":"Kenneth Blum,&nbsp;Mark S Gold,&nbsp;Jean L Cadet,&nbsp;David Baron,&nbsp;Abdalla Bowirrat,&nbsp;Panayotis K Thanos,&nbsp;Raymond Brewer,&nbsp;Rajendra D Badgaiyan,&nbsp;Marjorie C Gondré-Lewis","doi":"10.2174/2211556009666210108112737","DOIUrl":"https://doi.org/10.2174/2211556009666210108112737","url":null,"abstract":"<p><strong>Background: </strong>Repeated cocaine administration changes histone acetylation and methylation on Lys residues and Deoxyribonucleic acid (DNA) within the nucleus accumbens (NAc). Recently Nestler's group explored histone Arg (R) methylation in reward processing models. Damez-Werno <i>et al.</i> (2016) reported that during human investigations and animal self-administration experiments, the histone mark protein-R-methyltransferase-6 (PRMT6) and asymmetric dimethylation of R2 on histone H3 (H3R2me2a) decreased in the rodent and cocaine-dependent human NAc. Overexpression of PRMT6 in D2-MSNs in all NAc neurons increased cocaine seeking, whereas PRMT6 overexpression in D1-MSNs protects against cocaine-seeking.</p><p><strong>Hypothesis: </strong>The hypothesis is that dopaminylation (H3R2me2a binding) occurs in psychostimulant use disorder (PSU), and the binding inhibitor Srcin1, like the major DRD2 A2 allelic polymorphism, protects against psychostimulant seeking behavior by normalizing nucleus accumbens (NAc) dopamine expression.</p><p><strong>Discussion: </strong>Numerous publications confirmed the association between the DRD2 <b><i>Taq A1</i></b> allele (30-40 lower D2 receptor numbers) and severe cocaine dependence. Lepack <i>et al.</i> (2020) found that acute cocaine increases dopamine in NAc synapses, and results in histone H3 glutamine 5 dopaminylation (H3Q5dop) and consequent inhibition of D2 expression. The inhibition increases with chronic cocaine use and accompanies cocaine withdrawal. They also found that the Src kinase signaling inhibitor 1 (Srcin1 or p140CAP) during cocaine withdrawal reduced H3R2me2a binding. Consequently, this inhibited dopaminylation induced a \"homeostatic brake.\"</p><p><strong>Conclusion: </strong>The decrease in Src signaling in NAc D2-MSNs, (like the DRD2 Taq A2 allele, a well-known genetic mechanism protective against SUD) normalizes the NAc dopamine expression and decreases cocaine reward and motivation to self-administer cocaine. The Srcin1 may be an important therapeutic target.</p>","PeriodicalId":10751,"journal":{"name":"Current Psychopharmacology","volume":"11 1","pages":"11-17"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426774/pdf/nihms-1668752.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40336360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}